NCT07118618 Probenecid Administration for Alcohol Craving and Consumption
| NCT ID | NCT07118618 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Brown University |
| Condition | Alcohol Use Disorder (AUD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2026-03-14 |
| Primary Completion | 2030-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 120 participants in total. It began in 2026-03-14 with a primary completion date of 2030-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study proposes a 16-week, between-subject, double-blind, randomized controlled trial (RCT) with probenecid (2g /day) compared to placebo in individuals with AUD to test if reduces craving and alcohol consumption.
Eligibility Criteria
Inclusion Criteria: * • Male or female, ≥18 years. * women \>7 drinks/week; men \>14 drinks/week. * meet moderate to severe AUD score for DSM-5 criteria. * Breath Alcohol Content (BrAC)=0.00 at each visit. * in good health as confirmed by medical history, physical examination and lab tests. * willing to adhere to the study procedures. * understand informed consent and questionnaires in English at an 8th grade level. Exclusion Criteria: * • Women who are breastfeeding or positive urine test for pregnancy. * clinically significant medical abnormalities: unstable hypertension, clinically significant abnormal EKG, bilirubin \>150% of the upper normal limit, ALT/AST \>300% the UNL, creatinine clearance ≤60 dl/min * meet DSM-5 criteria for a diagnosis of schizophrenia, bipolar disorder, or other psychoses * medications that reduce alcohol consumption (naltrexone, disulfiram). * use aspirin (salicylates may reduce effect of probenecid), penicillin, methotrexate (may increase concentration). * history of suicide attempts in the last three years. * current diagnosis of a moderate or severe cannabis use disorder as assessed by self-report, SCID-E for SUD, and urine toxicology screen at baseline. * current diagnosis of another substance disorder at any severity, other than nicotine, as assessed by self-report, SCID-E for SUD, and urine toxicology screen at baseline. * current use of medications that may interact with probenecid. * history of hypersensitivity to sulfa drugs.
Contact & Investigator
Carolina Haass-Koffler, PharmD, PhD
PRINCIPAL INVESTIGATOR
Brown Univiversity
Frequently Asked Questions
Who can join the NCT07118618 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Alcohol Use Disorder (AUD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07118618 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07118618 currently recruiting?
Yes, NCT07118618 is actively recruiting participants. Contact the research team at brian_gully@brown.edu for enrollment information.
Where is the NCT07118618 trial being conducted?
This trial is being conducted at Providence, United States.
Who is sponsoring the NCT07118618 clinical trial?
NCT07118618 is sponsored by Brown University. The principal investigator is Carolina Haass-Koffler, PharmD, PhD at Brown Univiversity. The trial plans to enroll 120 participants.